ReviewInternational journal of molecular sciences2017
The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy.
Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Recent Advances in the Development and Efficacy of Anti-Cancer Vaccines-A Narrative Review.Vaccines · 2025Review
- Neoantigen Identification and Dendritic Cell-Based Vaccines for Lung Cancer Immunotherapy.Vaccines · 2024Review
- DNA vaccines as promising immuno-therapeutics against cancer: a new insight.Frontiers in immunology · 2024Review
- The future of cancer immunotherapy: DNA vaccines leading the way.Medical oncology (Northwood, London, England) · 2023Review
- Targeted Microbubbles for Drug, Gene, and Cell Delivery in Therapy and Immunotherapy.Pharmaceutics · 2023Review
- An Overview: Genetic Tumor Markers for Early Detection and Current Gene Therapy Strategies.Cancer informatics · 2023Review
- Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research.Frontiers in veterinary science · 2022Article
- 4-1BBL as a Mediator of Cross-Talk between Innate, Adaptive, and Regulatory Immunity against Cancer.International journal of molecular sciences · 2021Review
- Methylselenol producing selenocompounds enhance the efficiency of mammaglobin-A peptide vaccination against breast cancer cells.Oncology letters · 2019Article
- Article
- Cancer DNA vaccines: current preclinical and clinical developments and future perspectives.Journal of experimental & clinical cancer research : CR · 2019Review
- Immunogenicity of Tumor Initiating Stem Cells: Potential Applications in Novel Anticancer Therapy.Frontiers in oncology · 2019Review
- Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
DNA-based vaccine strategy is increasingly realized as a viable cancer treatment approach. Strategies to enhance immunogenicity utilizing tumor associated antigens have been investigated in several pre-clinical and clinical studies. The promising outcomes of these studies have suggested that DNA-based vaccines induce potent T-cell effector responses and at the same time cause only minimal side-effects to cancer patients. However, the immune evasive tumor microenvironment is still an important hindrance to a long-term vaccine success. Several options are currently under various stages of study to overcome immune inhibitory effect in tumor microenvironment. Some of these approaches include, but are not limited to, identification of neoantigens, mutanome studies, designing fusion plasmids, vaccine adjuvant modifications, and co-treatment with immune-checkpoint inhibitors. In this review, we follow a Porter's analysis analogy, otherwise commonly used in business models, to analyze various immune-forces that determine the potential success and sustainable positive outcomes following DNA vaccination using non-viral tumor associated antigens in treatment against cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.